Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $75.71

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned a consensus recommendation of “Hold” from the nineteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $76.67.

Several research firms have recently commented on CRSP. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $88.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, June 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Finally, Citigroup dropped their price objective on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd.

Insider Activity

In related news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Riggs Asset Managment Co. Inc. increased its stake in CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the last quarter. Orion Capital Management LLC increased its holdings in shares of CRISPR Therapeutics by 44.0% during the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after buying an additional 220 shares during the last quarter. National Bank of Canada FI raised its position in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares during the period. Larson Financial Group LLC boosted its holdings in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC grew its position in CRISPR Therapeutics by 7.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock valued at $286,000 after acquiring an additional 300 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

CRSP opened at $51.11 on Wednesday. The business has a 50 day simple moving average of $57.20 and a 200-day simple moving average of $63.27. The stock has a market capitalization of $4.34 billion, a P/E ratio of -18.79 and a beta of 1.70. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. CRISPR Therapeutics’s revenue for the quarter was down 99.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.67) earnings per share. Research analysts anticipate that CRISPR Therapeutics will post -5.52 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.